Tranquility Partners’s iShares Biotechnology ETF IBB Stock Holding History

Tranquility Partners’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,325	Closed	-$295K	–	218
2023 Q2	$295K	Buy	+2,325	New	+$302K	0.13%	164
2023 Q1	–	Sell	-2,325	Closed	-$305K	–	211
2022 Q4	$305K	Buy	+2,325	New	+$300K	0.16%	142
2022 Q1	–	Sell	-1,515	Closed	-$231K	–	224
2021 Q4	$231K	Buy	+1,515	New	+$235K	0.11%	196

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Tranquility Partners's IBB Position: Q3 2023 in Review

Tranquility Partners sold out of iShares Biotechnology ETF (IBB) in Q3 2023, closing a stake of 2,325 shares — an estimated $295K sold.

Tranquility Partners first reported a position in IBB in Q4 2021 and held it in 3 quarters. The position peaked at $305K in Q4 2022. 832 funds tracked by Wall St. Rank hold IBB as of Q3 2023.

Tranquility Partners reported no remaining iShares Biotechnology ETF position as of Q3 2023 after selling out during the quarter.
Tranquility Partners sold 2,325 iShares Biotechnology ETF shares in Q3 2023, an estimated $295K.
Tranquility Partners first reported a position in iShares Biotechnology ETF in Q4 2021 and held it in 3 quarters.
Tranquility Partners's iShares Biotechnology ETF position peaked at $305K in Q4 2022.
832 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2023.

Based on Tranquility Partners's 13F filing for Q3 2023, filed 31 Oct 2023.